{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:39:39Z","timestamp":1783226379240,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.euros.2021.05.003","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T20:34:31Z","timestamp":1623098071000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-2394","authenticated-orcid":false,"given":"Yoshiyuki","family":"Miyazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushige","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2021.05.003_bib0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2021.05.003_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrurol.2014.42","article-title":"Prostate cancer in Asian man","volume":"11","author":"Ito","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2021.05.003_bib0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/iju.12907","article-title":"Novel agents for castration-resistant prostate cancer: early experience and beyond","volume":"23","author":"Fujimoto","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2021.05.003_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.euros.2021.05.003_bib0045","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0050","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.1991.03460050072023","article-title":"Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group","volume":"265","author":"Chodak","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2021.05.003_bib0060","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0065","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","article-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","volume":"67","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.euros.2021.05.003_bib0070","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.euros.2021.05.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.10.020","article-title":"Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer","volume":"37","author":"Shiota","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/jcm8040489","article-title":"Higher serum testosterone levels associated with favorable prognosis in enzalutamide- and abiraterone-treated castration-resistant prostate cancer","volume":"8","author":"Sakamoto","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0085","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.urolonc.2019.04.026","article-title":"Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer","volume":"37","author":"Hashimoto","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2021.05.003_bib0095","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1373\/clinchem.2011.181735","article-title":"Accuracy of first and second generation testosterone assays and improvement through sample extraction","volume":"58","author":"Groenestege","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.euros.2021.05.003_bib0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pros.23804","article-title":"Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide","volume":"79","author":"Lolli","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2021.05.003_bib0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/pros.23938","article-title":"Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel","volume":"80","author":"Ando","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2021.05.003_bib0115","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","article-title":"Treatment of mCRPC in the AR-axis-targeted therapy-resistant state","volume":"26","author":"Chi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0120","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0125","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","article-title":"Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone","volume":"30","author":"Efstathiou","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2021.05.003_bib0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2021.05.003_bib0135","first-page":"485","article-title":"Cancer-related fatigue during combined treatment of androgen deprivation therapy and radiotherapy is associated with mitochondrial dysfunction","volume":"45","author":"Feng","year":"2020","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.euros.2021.05.003_bib0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1754-9485.12922","article-title":"Assessment and predictors of fatigue in men with prostate cancer receiving radiotherapy and androgen deprivation therapy","volume":"63","author":"Bandara","year":"2019","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832100094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832100094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:06:13Z","timestamp":1762977973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266616832100094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"alternative-id":["S266616832100094X"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2021.05.003","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2021.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}